NVG-291
Small Molecule Target: PTPσ, LAR family phosphatases, CSPG-PTPσ, CSPG
NervGen Pharma
Pipeline (4 active programs)
NVG-300
Peptide Target: PTPσ, LAR family phosphatases, CSPG
- Ischemic Stroke
- Spinal Cord Injury
- Undisclosed indication
Discontinued (1)
- NVG-300 — Amyotrophic Lateral Sclerosis · preclinical validation in ALS will not proceed at this time
Biotech Distilled coverage (10)
- 2026-07-02 UPDATE: NervGen Pharma (NGEN) — A $50M ATM Five Weeks After the “Fully Funded” Raise
- 2026-05-26 UPDATE: NervGen Pharma (NGEN) — The Gait Data Lands the Day the Deal Closes 🔒 Paid
- 2026-05-22 UPDATE: NervGen Pharma (NGEN) — The Deal Prints. Now You Can See the Cap Table. 🔒 Paid
- 2026-05-21 UPDATE: NervGen Pharma (NGEN) — The Prospectus Hits the Wire
- 2026-05-16 UPDATE: NervGen Pharma (NGEN) — Management Just Put a Date on the Dilution Gap 🔒 Paid
- 2026-04-28 UPDATE: NervGen Pharma (NGEN) — The CFO Watch Item Just Resolved 🔒 Paid
- 2026-04-27 UPDATE: NervGen Pharma (NGEN) - The Sarepta Playbook Worked 🔒 Paid
- 2026-03-07 UPDATE: NervGen (NGEN): Adopting the Sarepta Playbook Ahead of FDA Negotiations 🔒 Paid
- 2026-02-14 UPDATE: NervGen Pharma (NGENF): A C-Suite Shuffle on the Edge of the Dilution Gap
- 2026-01-14 NervGen Pharma (NGENF): Scientific Deep Dive for NVG-291 and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.